Abiopharma

🔍 Hulls Chris (Director)

Company: Life360, Inc. (LIF)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Acquired 50,000 shares of Common Stock at $7.28 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 469,554.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 47,993 shares of Common Stock at $2.53 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 517,547.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 114,509 shares of Common Stock at $8.19 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 632,056.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 231,434 shares of Common Stock at $46.78 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 400,622.00 | transaction_form_type: 4 | Footnotes: F3, F1
• Sold 18,566 shares of Common Stock at $47.58 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 382,056.00 | transaction_form_type: 4 | Footnotes: F4, F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: H | nature_of_ownership: Held by the Robin Hulls 2023 Irrevocable Trust | shares_owned_after: 195,312.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: H | nature_of_ownership: Held by the Rose Hulls 2023 Irrevocable Trust | shares_owned_after: 195,312.00 | Footnotes: F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-18 | Code: H | nature_of_ownership: Held by the Mckenzie Hulls 2023 Irrevocable Trust | shares_owned_after: 195,312.00 | Footnotes: F5
• Sold 47,993 shares of Stock Option (right to buy) at $2.53 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2028-07-16 | equity_swap_involved: 0 | shares_owned_after: 1,167,393.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 50,000 shares of Stock Option (right to buy) at $7.28 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2030-07-30 | equity_swap_involved: 0 | shares_owned_after: 180,000.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 114,509 shares of Stock Option (right to buy) at $8.19 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2028-05-20 | equity_swap_involved: 0 | shares_owned_after: 11,292.00 | transaction_form_type: 4 | Footnotes: F6

Footnotes:

• F1: Includes common stock and the number of shares of common stock underlying Chess Depositary Interests ("CDIs") as converted on a 1:3 common stock to CDI ratio. The CDIs are traded on the Australian Securities Exchange (the "ASX") and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX.
• F2: Includes 134,496 restricted stock units previously granted, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting.
• F3: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $46.36 to $47.35, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range.
• F4: The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $47.36 to $48.30, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full details regarding the number of shares sold at each separate price within the range.
• F5: Represents shares of the Issuer's common stock underlying 585,938 CDIs.
• F6: The stock option is fully vested and exercisable.